---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037183"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:54:07.981348+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus reports Q3 net sales $120.8M (-6.1% YoY), raises 2023 adjusted EBITDA guidance

## Summary
- Net loss from continuing ops improved to $8.8M from $101.0M in Q3 2022; loss per share $0.12 vs $1.18.
- Adjusted EBITDA from continuing ops $21.7M, down 0.9% YoY; non-GAAP EPS $0.05 vs $0.18.
- Pain Treatments revenue grew 3.1% YoY to $53.7M; Surgical Solutions up 5.7% in U.S.
- Raised full-year 2023 guidance: net sales $498-505M, adjusted EBITDA $84-87M.
- Restorative Therapies fell 34.8% due to Wound Business divestiture; underlying organic sales down 0.5%.

## SEC filing metadata
- accession: 0001628280-23-037183
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/0001628280-23-037183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/bvs-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037183
- JSON: https://secwatch.observer/filing/0001628280-23-037183.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037183.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported the three and nine months ended September 30, 2023 results: revenue $120.8 million, net income Net Loss from continuing operations of $8.8 million, EPS Loss per share of Class A common stock from continuing operations of $0.12. Guidance raised.
  - Period: the three and nine months ended September 30, 2023
  - Revenue: $120.8 million
  - Net income: Net Loss from continuing operations of $8.8 million
  - EPS: Loss per share of Class A common stock from continuing operations of $0.12
  - Guidance: raised
  - Result: reported results
  source text: a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: • Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/0001628280-23-037183-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.